Lead Generation and Optimization Based on Protein-Ligand Complementarity

This work proposes a computational procedure for structure-based lead generation and optimization, which relies on the complementarity of the protein-ligand interactions. This procedure takes as input the known structure of a protein-ligand complex. Retaining the positions of the ligand heavy atoms in the protein binding site it designs structurally similar compounds considering all possible combinations of atomic species (N, C, O, CH3, NH, etc). Compounds are ranked based on a score which incorporates energetic contributions evaluated using molecular mechanics force fields. This procedure was used to design new inhibitor molecules for three serine/threonine protein kinases (p38 MAP kinase, p42 MAP kinase (ERK2), and c-Jun N-terminal kinase 3 (JNK3)). For each enzyme, the calculations produce a set of potential inhibitors whose scores are in agreement with IC50 data and Ki values. Furthermore, the native ligands for each protein target, scored within the five top-ranking compounds predicted by our method, one of the top-ranking compounds predicted to inhibit JNK3 was synthesized and his inhibitory activity confirmed against ATP hydrolysis. Our computational procedure is therefore deemed to be a useful tool for generating chemically diverse molecules active against known target proteins.

[1]  Marianne A Grant,et al.  Protein structure prediction in structure-based ligand design and virtual screening. , 2009, Combinatorial chemistry & high throughput screening.

[2]  Masilamani Elizabeth Sobhia,et al.  Fingerprint Directed Scaffold Hopping for Identification of CCR2 Antagonists , 2008, J. Chem. Inf. Model..

[3]  Aniko Simon,et al.  eHiTS: a new fast, exhaustive flexible ligand docking system. , 2007, Journal of molecular graphics & modelling.

[4]  Anna Linusson,et al.  SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.

[5]  Hiroshi Yamashita,et al.  A Quantitative Approach to the Estimation of Chemical Space from a Given Geometry by the Combination of Atomic Species , 2007 .

[6]  Massimo Baroni,et al.  Virtual screening for novel openers of pancreatic K(ATP) channels. , 2007, Journal of medicinal chemistry.

[7]  Gary Larson,et al.  Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study. , 2007, Bioorganic & medicinal chemistry letters.

[8]  Mohammed M. Abadleh,et al.  From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. , 2007, Journal of medicinal chemistry.

[9]  Xiaoling Xie,et al.  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.

[10]  Hongyu Zhao,et al.  Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. , 2007, Drug discovery today.

[11]  G. Narahari Sastry,et al.  Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study , 2007, J. Comput. Aided Mol. Des..

[12]  Kazuto Yamazaki,et al.  Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution. , 2006, Bioorganic & medicinal chemistry letters.

[13]  G. Schneider,et al.  Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts , 2006, ChemMedChem.

[14]  Peter Willett,et al.  Scaffold Hopping Using Clique Detection Applied to Reduced Graphs , 2006, J. Chem. Inf. Model..

[15]  Jonas Boström,et al.  Computational chemistry-driven decision making in lead generation. , 2006, Drug discovery today.

[16]  Ismael Zamora,et al.  Virtual Screening and Scaffold Hopping Based on GRID Molecular Interaction Fields , 2005, J. Chem. Inf. Model..

[17]  Jean-Pierre Gotteland,et al.  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.

[18]  J. Jenkins,et al.  A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.

[19]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[20]  Philip M Dean,et al.  Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. , 2004, Journal of medicinal chemistry.

[21]  Michelle Browner,et al.  Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. , 2003, Journal of medicinal chemistry.

[22]  J. Lisnock,et al.  The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. , 2003, Chemistry & biology.

[23]  Andreas Zell,et al.  The Compressed Feature Matrix—a novel descriptor for adaptive similarity search , 2003, Journal of molecular modeling.

[24]  G. Rishton Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[25]  Peter Willett,et al.  Scaffold Searching: Automated Identification of Similar Ring Systems for the Design of Combinatorial Libraries , 2002 .

[26]  Lars Naerum,et al.  Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[27]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[28]  R. Cramer,et al.  Toward general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. , 2000, Journal of medicinal chemistry.

[29]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[30]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[31]  J. Mason,et al.  New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.

[32]  Frank T. Coppo,et al.  Synthesis of 1-Methyl-7-(trifluoromethyl)-1H-pyrido[2,3-c][1,2]thiazin-4(3H)-one 2,2-Dioxide. , 1998 .

[33]  P. Caron,et al.  Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. , 1998, Structure.

[34]  Frank T. Coppo,et al.  Novel heterocycles. Synthesis of 2,3-dihydro-6-methyl-2-phenyl-4H,6H-pyrano[3,2-c][2,1]benzothiazin-4-one 5,5-dioxide and related compounds , 1998 .

[35]  Eugene I. Shakhnovich,et al.  SMOG : DE NOVO DESIGN METHOD BASED ON SIMPLE, FAST, AND ACCURATE FREE ENERGY ESTIMATES. 2. CASE STUDIES IN MOLECULAR DESIGN , 1997 .

[36]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[37]  D K Gehlhaar,et al.  De novo design of enzyme inhibitors by Monte Carlo ligand generation. , 1995, Journal of medicinal chemistry.

[38]  P Willett,et al.  Docking small-molecule ligands into active sites. , 1995, Current opinion in biotechnology.

[39]  Daniel A. Gschwend,et al.  Orientational sampling and rigid‐body minimization in molecular docking , 1993, Proteins.

[40]  A Itai,et al.  Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. , 1993, Journal of medicinal chemistry.

[41]  Hans-Joachim Böhm,et al.  LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads , 1992, J. Comput. Aided Mol. Des..

[42]  W L Jorgensen,et al.  Rusting of the lock and key model for protein-ligand binding. , 1991, Science.

[43]  H. Scheraga,et al.  Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Coppola,et al.  Novel heterocycles. 4. Synthesis of the pyrido[2,3-c]-1,2-thiazine ring system , 1979 .

[45]  J. Lombardino Preparation of some 4‐hydroxyl‐1‐methyl‐1H‐2,1‐benzothiazine‐3‐carboxanilide 2,2‐dioxides , 1972 .